Hoppe, JE; Kasi, AS; Pittman, JE; Jensen, R; Thia, LP; Robinson, P; Tirakitsoontorn, P; ... Davies, G; + view all (2025) Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. The Lancet Respiratory Medicine 10.1016/S2213-2600(24)00407-7. (In press). Green open access